CRO support for ncats animal model development and in vivo pharmacology studies and related services

Ended Indefinite Delivery Contract Awarded Last action

Contract number
75N95019D00012
Awardee
Awarding agency
Task orders
13 $18,538,060 obligated

Award facts

Opportunity
Combined order value
  • $18,538,060 Current, with exercised options
  • $26,337,630 Potential, with all options
Last date to order 100% complete
IDV ceiling 48% used
$38,489,089.00
Award type
Single award
Who can order
Only the awarding agency
Funding agency
National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)

Award details come from SAM.gov/FPDS.

Task orders

Task order Ordering agency Obligated Awarded
Efficacy and safety evaluation of lead gene therapy candidate in neuromuscular junction (NMJ) disease mouse models… 75N95023F00002 National Institute on Drug Abuse (NIH) $1,899,147
Characterization of spontaneous osteogenesis after surgical segmental bone defect in a large animal 75N95023F00001 National Institute on Drug Abuse (NIH) $385,704
Bioanalytical supports for a GLP TOX/biodistribution study in mini-pigs 75N95022F00001 National Institute on Drug Abuse (NIH) $792,052
Efficacy and safety evaluation of a lead gene therapy candidate in methyl melanomic acidemia (mmab) disease mouse… 75N95021F00002 National Institute on Drug Abuse (NIH) $452,931
Characterization of a non-paralyzing bont-based biopharmaceutical for the treatment of neuropathic pain 75N95021F00001 National Institute on Drug Abuse (NIH) $1,633,884
Natural history studies in neuromuscular junction (NMJ) disease mouse models. Period of performance september 28… 75N95020F00003 National Institute on Drug Abuse (NIH) $2,011,717
Efficacy and safety evaluation of a lead gene therapy candidate in propionic acidemia (PA) disease mouse models and… 75N95020F00005 National Institute on Drug Abuse (NIH) $2,274,579
Characterization of a downstream gene therapeutic for the reparative treatment of severe fractures period of… 75N95020F00004 National Institute on Drug Abuse (NIH) $1,317,349
Characterization of a non-addictive small molecule therapeutics for the management of non-cancer pain period of… 75N95020F00002 National Institute on Drug Abuse (NIH) $2,327,263
Task order entitled, "pharmacodynamics of the MAS-related gene X2 (MRGX2) antagonist SYR268215 in the humanized MRGX2… 75N95020F00001 National Institute on Drug Abuse (NIH) $1,694
Evaluation of drug efficacy in a guinea PIG model of neonatal opioid withdrawal syndrome 75N95019F00089 National Institute on Drug Abuse (NIH) $179,684
Evaluation of drug efficacy in a RAT model of neuropathic pain 75N95019F00090 National Institute on Drug Abuse (NIH) $292,814
Disease model characterization and development of assays to evaluate and measure pain in a porcine model for sickle… 75N95019F00088 National Institute on Drug Abuse (NIH) $4,969,241
Show all 13

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00006 $0
Supplemental Agreement for work within scope P00005 $0
Vendor DUNS or Name Change - Non-Novation P00004 $0
Supplemental Agreement for work within scope P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $0

Quick answers

Who was awarded contract 75N95019D00012?

75N95019D00012 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on July 1, 2019.

How much is contract 75N95019D00012 worth?

Orders under 75N95019D00012 have obligated $18,538,060. Their combined potential value, with all options, is $26,337,630. 75N95019D00012's own ceiling is $38,489,089.

How many orders have been placed under contract 75N95019D00012?

13 orders have been placed under 75N95019D00012, the latest on September 29, 2023.

Which agency awarded contract 75N95019D00012?

National Institute on Drug Abuse (National Institutes of Health) awarded 75N95019D00012, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).

Who can order from contract 75N95019D00012?

75N95019D00012 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract 75N95019D00012 competed?

The extent of competition for 75N95019D00012 was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV